Syros Pharmaceuticals Stock Alpha and Beta Analysis
| SYRS Stock | USD 0.27 0.02 8.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Syros Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Syros Pharmaceuticals over a specified time horizon. Remember, high Syros Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Syros Pharmaceuticals' market risk premium analysis include:
Beta 0.84 | Alpha (0.62) | Risk 14.72 | Sharpe Ratio (0.03) | Expected Return (0.49) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Syros |
Syros Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Syros Pharmaceuticals market risk premium is the additional return an investor will receive from holding Syros Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Syros Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Syros Pharmaceuticals' performance over market.| α | -0.62 | β | 0.84 |
Syros Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Syros Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Syros Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Syros Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Syros Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Syros Pharmaceuticals shares will generate the highest return on investment. By understating and applying Syros Pharmaceuticals stock market price indicators, traders can identify Syros Pharmaceuticals position entry and exit signals to maximize returns.
Syros Pharmaceuticals Return and Market Media
The median price of Syros Pharmaceuticals for the period between Sun, Sep 1, 2024 and Sat, Nov 30, 2024 is 1.95 with a coefficient of variation of 44.17. The daily time series for the period is distributed with a sample standard deviation of 0.76, arithmetic mean of 1.71, and mean deviation of 0.57. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Buying President CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc | 09/12/2024 |
2 | Syros Pharmaceuticals Inc Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm | 09/25/2024 |
3 | Disposition of 6301 shares by Roth David of Syros Pharmaceuticals at 2.22 subject to Rule 16b-3 | 10/18/2024 |
4 | Syros Pharmaceuticals Inc Is Being Investigated For Securities Fraud And Shareholders With Losses Are Encouraged To Contact The Schall Law Firm | 10/23/2024 |
5 | Acquisition by Fanucci Marsha of 4000 shares of Syros Pharmaceuticals subject to Rule 16b-3 | 11/07/2024 |
6 | Kias Upcoming SUV Christened Syros Will Rival Tata Punch, Maruti Fronx | 11/11/2024 |
7 | Syros Pharmaceuticals Earns Market Perform Rating from JMP Securities | 11/13/2024 |
8 | Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal | 11/14/2024 |
9 | Disposition of 46657 shares by Quirk Gerald E of Syros Pharmaceuticals at 0.2212 subject to Rule 16b-3 | 11/19/2024 |
10 | Syros pharmaceuticals chief development officer sells shares for 7,949 | 11/20/2024 |
11 | Disposition of 134713 shares by Simonian Nancy A of Syros Pharmaceuticals at 0.2653 subject to Rule 16b-3 | 11/25/2024 |
12 | Kia Syros Compact SUV To Get Panoramic Sunroof- Teaser Confirms | 11/26/2024 |
About Syros Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Syros or other stocks. Alpha measures the amount that position in Syros Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 46.29 | 41.55 | 47.79 | 45.4 | PTB Ratio | 2.39 | 0.36 | 13.24 | 13.91 |
Syros Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Syros Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Syros Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Syros Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Syros Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Syros Pharmaceuticals' management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Syros Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Syros Stock Analysis
When running Syros Pharmaceuticals' price analysis, check to measure Syros Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syros Pharmaceuticals is operating at the current time. Most of Syros Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syros Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syros Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syros Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.